Invesco’s XTL Biopharmaceuticals XTLB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-6,490
| Closed | -$35K | – | 3709 |
|
|
2019
Q3 | $35K | Hold |
6,490
| – | – | ﹤0.01% | 3657 |
|
|
2019
Q2 | $52K | Hold |
6,490
| – | – | ﹤0.01% | 3703 |
|
|
2019
Q1 | $61K | Hold |
6,490
| – | – | ﹤0.01% | 3693 |
|
|
2018
Q4 | $45K | Hold |
6,490
| – | – | ﹤0.01% | 3699 |
|
|
2018
Q3 | $57K | Hold |
6,490
| – | – | ﹤0.01% | 3811 |
|
|
2018
Q2 | $48K | Hold |
6,490
| – | – | ﹤0.01% | 3805 |
|
|
2018
Q1 | $45K | Hold |
6,490
| – | – | ﹤0.01% | 3695 |
|
|
2017
Q4 | $59K | Hold |
6,490
| – | – | ﹤0.01% | 3623 |
|
|
2017
Q3 | $62K | Hold |
6,490
| – | – | ﹤0.01% | 3628 |
|
|
2017
Q2 | $82K | Hold |
6,490
| – | – | ﹤0.01% | 3655 |
|
|
2017
Q1 | $68K | Sell |
6,490
-1
| -0% | -$11 | ﹤0.01% | 3663 |
|
|
2016
Q4 | $82K | Hold |
6,491
| – | – | ﹤0.01% | 3618 |
|
|
2016
Q3 | $123K | Hold |
6,491
| – | – | ﹤0.01% | 3579 |
|
|
2016
Q2 | $151K | Hold |
6,491
| – | – | ﹤0.01% | 3592 |
|
|
2016
Q1 | $134K | Hold |
6,491
| – | – | ﹤0.01% | 3625 |
|
|
2015
Q4 | $183K | Hold |
6,491
| – | – | ﹤0.01% | 3582 |
|
|
2015
Q3 | $203K | Hold |
6,491
| – | – | ﹤0.01% | 3576 |
|
|
2015
Q2 | $243K | Hold |
6,491
| – | – | ﹤0.01% | 3652 |
|
|
2015
Q1 | $299K | Hold |
6,491
| – | – | ﹤0.01% | 3528 |
|
|
2014
Q4 | $257K | Hold |
6,491
| – | – | ﹤0.01% | 3548 |
|
|
2014
Q3 | $221K | Hold |
6,491
| – | – | ﹤0.01% | 3623 |
|
|
2014
Q2 | $397K | Hold |
6,491
| – | – | ﹤0.01% | 3443 |
|
|
2014
Q1 | $473K | Hold |
6,491
| – | – | ﹤0.01% | 3424 |
|
|
2013
Q4 | $376K | Hold |
6,491
| – | – | ﹤0.01% | 3584 |
|
|
2013
Q3 | $692K | Buy |
+6,491
| New | +$801K | ﹤0.01% | 3233 |
|
Other funds holding XTLB
Invesco's XTLB Position: Q4 2019 in Review
Invesco sold out of XTL Biopharmaceuticals (XTLB) in Q4 2019, closing a stake of 6,490 shares — an estimated $35K sold.
Invesco first reported a position in XTLB in Q3 2013 and held it in 25 quarters. The position peaked at $692K in Q3 2013. 4 funds tracked by Wall St. Rank hold XTLB as of Q4 2019.
- Invesco reported no remaining XTL Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Invesco sold 6,490 XTL Biopharmaceuticals shares in Q4 2019, an estimated $35K.
- Invesco first reported a position in XTL Biopharmaceuticals in Q3 2013 and held it in 25 quarters.
- Invesco's XTL Biopharmaceuticals position peaked at $692K in Q3 2013.
- 4 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q4 2019.
Based on Invesco's 13F filing for Q4 2019, filed 14 Feb 2020.